Mark P. Lappe serves as the Chief Executive Officer and Chairman of the Board of Directors at INHIBRX BIOSCIENCES INC., a biopharmaceutical company focused on developing novel biologic therapeutic candidates. With a robust background in the biotechnology and pharmaceutical industries, Lappe has been instrumental in steering the company towards its mission of creating innovative treatments for cancer and other debilitating diseases. Under his leadership, INHIBRX has made significant strides in advancing its pipeline of therapeutic candidates, which includes targeted therapies designed to address unmet medical needs. Before joining INHIBRX, Lappe held various leadership positions in the biotech sector, where he gained extensive experience in drug development, strategic planning, and corporate governance. His career is marked by a series of successful initiatives that have propelled companies forward in their research and development efforts. At INHIBRX, Lappe's strategic vision has been pivotal in securing partnerships and investments that have fueled the company's growth. His commitment to advancing scientific innovation and improving patient outcomes continues to drive INHIBRX's mission and solidify its position in the competitive biopharmaceutical landscape.